Financial Review: Luna Innovations (NASDAQ:LUNA) and iSpecimen (NASDAQ:ISPC)

iSpecimen (NASDAQ:ISPC) and Luna Innovations (NASDAQ:LUNA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

Insider and Institutional Ownership

10.5% of iSpecimen shares are held by institutional investors. Comparatively, 48.8% of Luna Innovations shares are held by institutional investors. 6.1% of Luna Innovations shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares iSpecimen and Luna Innovations’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
iSpecimen $8.18 million 6.67 -$4.65 million N/A N/A
Luna Innovations $82.68 million 2.86 $3.29 million ($0.01) -740.00

Luna Innovations has higher revenue and earnings than iSpecimen.

Profitability

This table compares iSpecimen and Luna Innovations’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
iSpecimen N/A N/A N/A
Luna Innovations -0.26% 5.66% 3.36%

Analyst Recommendations

This is a summary of current recommendations and price targets for iSpecimen and Luna Innovations, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
iSpecimen 0 0 1 0 3.00
Luna Innovations 0 1 1 0 2.50

iSpecimen presently has a consensus target price of $20.00, suggesting a potential upside of 220.00%. Luna Innovations has a consensus target price of $10.50, suggesting a potential upside of 41.89%. Given iSpecimen’s stronger consensus rating and higher possible upside, analysts clearly believe iSpecimen is more favorable than Luna Innovations.

Summary

Luna Innovations beats iSpecimen on 6 of the 10 factors compared between the two stocks.

About iSpecimen

iSpecimen, Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables researchers to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts.

About Luna Innovations

Luna Innovations, Inc. engages in the development and manufacture of fiber optic test and measurement, sensing and instrumentation products for the automotive, aerospace, energy and infrastructure industries. It operates through the following segments: Lightwave and Luna Labs. The Lightwave segment develops, manufactures and markets distributed fiber optic sensing products and fiber optic communications test and control products. The Luna Labs segment performs applied research principally in the areas of sensing and instrumentation, advanced materials and health science. The company was founded by Kent A. Murphy in July 1990 and is headquartered in Roanoke, VA.

Receive News & Ratings for iSpecimen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iSpecimen and related companies with MarketBeat.com's FREE daily email newsletter.